SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
May 7, 2002
Date of Report (Date of earliest event reported)
---------------------
AMGEN INC.
(Exact name of registrant as specified in its charter)
Delaware 000-12477 95-3540776
(State or other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification Number)
Amgen Inc. 91320-1799
One Amgen Center Drive (Zip Code)
Thousand Oaks, CA
(Address of principal
executive offices)
805-447-1000
(Registrant's telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On May 7, 2002, Amgen Inc. purchased from F. Hoffman-La Roche Ltd.
("Roche") Roche's rights, assets and business related to Filgrastim and
pegfilgrastim in the European Union, Switzerland and Norway. With regard to the
EU, the effective date of the purchase is January 1, 2002. Under the terms of
the agreement between the parties, Amgen will pay Roche $137.5 million for this
acquisition. Roche will continue as the licensee for Filgrastim and
pegfilgrastim in certain countries in Eastern Europe, the Middle East, Africa,
Asia and Latin America.
The press release announcing the transaction is attached to this Current
Report as Exhibit 99.1.
Item 7(c). Exhibits.
See Exhibit Index.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
AMGEN INC.
Date: May 10, 2002 By: /s/ Richard D. Nanula
--------------------------------------
Name: Richard D. Nanula
Title: Executive Vice President,
Finance, Strategy and
Communications, and Chief
Financial Officer
2
EXHIBIT INDEX
Exhibit
Number Document Description
------- --------------------
99.1 Press Release dated May 7, 2002.
3